- For Regulatory Affairs: the initiative creates a new channel for industry input on scientific and regulatory gaps.
- For Clinical Development: QMIN could support collaboration around areas such as disease modelling and trial simulation.
- for data, modelling and digital teams: the discussions put governance, infrastructure and shared scientific resources firmly on the agenda.
FDA and Duke Move QMIN Forward: Quantitative Medicine Governance Takes Shape
The September 1 Innovation in Quantitative Medicine Summit was co-convened by Duke-Margolis and FDA’s Quantitative Medicine Center of Excellence. According to FDA, the meeting is intended to inform the establishment of QMIN and identify areas where coordinated collaboration could address important scientific and regulatory gaps.
The discussion also covers governance structures, incentives and resource-sharing mechanisms needed to sustain participation. Therefore, the initiative extends beyond individual modelling projects. FDA is examining how a durable network could support wider adoption of quantitative medicine throughout the drug development lifecycle.
What FDA’s QMIN Push Changes for Quantitative Drug Development
The Federal Register defines quantitative medicine approaches as the integration of mathematical and computational models with biological, clinical and statistical data to inform drug development, regulatory and clinical decisions. FDA says these methods have the potential to improve development efficiency, optimize treatment strategies and support better patient outcomes.
This distinction matters. The September 1 meeting does not establish a new validation rule or regulatory requirement. Instead, FDA is seeking input on where quantitative approaches could provide the greatest value and what infrastructure, standards and collaboration mechanisms may be needed.
FDA Maps the Gaps QMIN Must Solve Before Wider Adoption
FDA’s request for information highlights possible areas including disease modelling, trial simulation and integration of New Approach Methodologies. It also asks stakeholders where gaps exist in tools, standards and infrastructure. In addition, FDA is seeking views on governance, working groups, pilot projects, shared platforms, funding approaches and methods for measuring the value of future QMIN use cases.
That makes the initiative particularly relevant to organizations already using advanced modelling in clinical development or regulatory decision support.
If a quantitative model begins materially influencing a regulatory decision, should its governance remain within the modelling function, or become a formal cross-functional responsibility involving Regulatory, Quality and Clinical teams?
What Pharma Teams Should Watch as FDA Builds QMIN
The next major step is stakeholder feedback. FDA’s Federal Register notice remains open for comments until November 3, 2026, and submissions will help shape the network’s future structure, priorities and activities. Teams should also watch for additional FDA information on QMIN governance, priority use cases, demonstration projects and how different stakeholders will participate.
What Regulatory and Digital Teams Should Review Before QMIN Advances
- Review the FDA request for information and identify QMIN topics relevant to current development programs.
- Map where quantitative methods already influence clinical, regulatory or development decisions internally.
- Bring Regulatory, Clinical, modelling and data stakeholders together when evaluating potential feedback to FDA.
- Track future QMIN publications before changing internal processes or treating the initiative as a regulatory requirement.
How Digital Solutions Can Support Model-Driven Pharmaceutical Development
Zamann Pharma’s Digital Solutions for GMP-Regulated Operations service helps pharmaceutical teams implement and improve digital workflows while maintaining compliance, traceability, and system control. The support can include areas such as computerized-system validation, master-data management, digital process design, system implementation, and the controlled use of data across regulated operations.
Source: FDA